Medpace Holdings, Inc. (MEDP)
Nasdaq · Healthcare · Diagnostics & Research
$620.51+3.51%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $17.3B
- P/E (trailing)
- 36.4
- Forward P/E
- 32.1
- 52-week range
- $373.00 – $677.90
- 52-week change
- +12.71%
- EPS (trailing)
- $17.03
- Analyst rating
- 2.9 Hold
- Next earnings
- Oct 21, 2026
Fiscal year to Dec 2025
- Revenue
- $2.5B (+19.97%)
- Net income
- $451M
- Operating margin
- 21.1%
- Diluted EPS
- $15.28
- Free cash flow
- $682M
From the company’s annual report on SEC EDGAR.
About Medpace Holdings, Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Headquarters: Cincinnati, United States · 6,500 employees · medpace.com